Director · Viking Therapeutics, Inc. · Viking Therapeutics, Inc. — Stock Option (Right to Buy)
Side
A
Value
—
Shares
40.8K
Price
—
Executed
Aug 1, 2026
Disclosed
Aug 7, 2026
Disclosure timeline6 days from execution to publication · legal deadline 2 business days
Aug 1 executedAug 7, 2026 disclosed
VKTX · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing+6 / 15
Disclosed 5 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Viking Therapeutics, Inc. — Stock Option (Right to Buy)
Ticker
VKTX
Shares
40.8K
Price per share
$0
Execution date (reported)
Aug 1, 2026
Owned after transaction
40.8K shares
Days from execution to publication
6
What this establishes
Kelly-Gemmell Dorothy Elizabeth filed this Form 4 reporting a grant or award of VKTX on Aug 1, 2026. It became public on Aug 7, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director
Kelly-Gemmell Dorothy Elizabethcik:0002144542
Issuer
Viking Therapeutics, Inc.cik:0001607678
Revision history · 0
No field has changed since this record was first ingested.
